What’s It Worth? New Shingles Vaccine Offers a Chance to Measure the Value of Prevention
An economic analysis led by a U-M expert found reason to recommend Shingrix to everyone over age 50. As the vaccine hits the market, its merits will be continually evaluated.
December 01, 2017 7:00 AM